I Shoulson… - Movement Disorders, 2011 - Wiley Online Library In 1872, George Huntington described the key hereditary and clinical features of the disorder that was to bear his name,1 in the same era when Gregor Mendel was formulating the fundamental principles of genetics. Many decades passed before the significance of Huntington's ... Related articles - All 2 versions
SN Sivananthan… - Neurobiology of Aging, 2011 - Elsevier ... Abstract. Cystamine has demonstrated neuroprotective activity in a variety of studies, and is currently being evaluated in a human clinical trial in Huntington'sdisease (HD). ... Keywords: Huntingtondisease; Mouse models; Malonate; Cystamine; Neurodegeneration; Striatum. ... All 3 versions
I Munoz-Sanjuan… - J Clin Invest, 2011 - Am Soc Clin Investig Huntington disease (HD) is a dominantly inherited neurodegenerative disorder that results from expansion of the polyglutamine repeat in the huntingtin (HTT) gene. There are currently no effective treatments for this devastating disease. Given its monogenic nature, disease modification ... Cited by 1 - Related articles - All 3 versions
[HTML] from nih.govJ Labbadia, H Cunliffe, A Weiss… - The Journal of clinical …, 2011 - ncbi.nlm.nih.gov Huntington disease (HD) is a devastating neurodegenerative disorder for which there are no disease-modifying treatments. Previous studies have proposed that activation of the heat shock response (HSR) via the transcription factor heat shock factor 1 (HSF1) may be of ...
D Eidelberg… - J Clin Invest, 2011 - Am Soc Clin Investig Recent studies have focused on understanding the neural mechanisms underlying the emergence of clinical signs and symptoms in early stage Huntington disease (HD). Although cell-based assays have focused on cell autonomous effects of mutant huntingtin, animal HD models have ... Cited by 2 - Related articles - All 3 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
